US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
pharma · Growth Hormone Deficiency, Pediatric
Ascendis Pharma
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Palo Alto, USA HQ
2010 Founded
5 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 7
- Patents
- 6
Ascendis Pharma pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ascendis Pharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Ascendis Pharma in public FDA and regional records.
-
lonapegsomatropin
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Ascendis Pharma's portfolio. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
somatropin
Systemic hormonal preparations (H01)US regulatory status: approved. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
Development asset linked to Ascendis Pharma in public FDA and regional records.